Clinical Trials Browser

Interventional × Recurrence × NVP-BKM120 × Clear all

NCT01623349 2021-02-10

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Phase 1 Completed

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Recurrence

NCT01737450 2019-06-24

PIK-ORL

Phase 2 Completed

Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence, Disease Progression

NCT02301364 2017-10-19

Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Phase 2 Completed

4 enrolled 11 charts

Lymphoma, Recurrence